Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CAPLYTA (lumateperone) — U.S. sales by Quarter
CAPLYTA (lumateperone) — U.S. sales ($M) ($M)
Johnson & Johnson CAPLYTA (lumateperone) — U.S. sales: $398M in Q3 2026, up 65.8% from a year earlier. That is the highest of the 10 quarters on record here.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-21) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CAPLYTA (lumateperone) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 398 | +65.8% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 361 | +71.1% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 270 | – | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 249 | – | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 240 | – | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 211 | – | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 0 | – | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 0 | – | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 0 | – | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Form 10-Q (filed 2025-07-24) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson CAPLYTA (lumateperone) — U.S. sales ($M), quarterly Q2 2024–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-caplyta-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.